| [1] |
Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity, 2000, 12:121 -127.
|
| [2] |
黄仕和.趋化因子的研究进展.生物化学与生物物理进展,1998,25:485 -487.
|
| [3] |
Pellegrino A, Yacca A, Scavellic C, et al . Chemokines and tumors. Recenti Prog Med,2002,93:642 -654.
|
| [4] |
Horuk R. Chemokine receptors. Cytokine Growth Factor Rev,2001,12:313 -335.
|
| [5] |
Murphy P M. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev ,2002 ,54 :227 -229.
|
| [6] |
胡凯猛,熊俊. 肿瘤微环境与趋化因子家族. 国外医学·肿瘤学分册,2005,32:247 -250.
|
| [7] |
Balkwill F. Chemokine biology in cancer. Semin Immunol 2003,15:49 -55.
|
| [8] |
Vicari A P, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev,2002,13:143 -154.
|
| [9] |
Lowman H B, Slagle P H, DeForge L E, et al. Exchanging interleukin-8 and melanoma growth-stimulating activity receptor binding specificities. J Biol Chem,1996,271:14 344 -14 352.
|
| [10] |
Strieter R M, Polverini P J, Kunkel S L, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem,1995,270:27 348 -27 357.
|
| [11] |
Wilkinson B, Owen J J, Jenkinson E J, et al. Factors regulating stemcell recruitment to the fetal thymus. J Immunol,1999,162:3873 -3881.
|
| [12] |
Salcedo R, Ponce M L,Young H A, et al. Human endothelial cells express CCR2 and respond to MCP-1:direct role of MCP-1 in angiogenesis and tumor progression. Blood,2000,96:34 -40.
|
| [13] |
Sehneider G P, Salcedo R,Welniak L A, et al. The diverse role of chemokines in tumor progression: prospects for intervention. Int J Mol Med,2001,8:235 -244.
|
| [14] |
Muller A, Homey B, Soto H, et al . Involvement of chemokine receptors in breast cancer metastasis. Nature,2001,410:50 -56.
|
| [15] |
Allinen M, Beroukhim R,Cai L,et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell ,2004,6:17 -32.
|
| [16] |
Orimo A, Gupta P B, Sgroi D C, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1 /CXCL12 secretion. Cell,2005,121:335 -348.
|
| [17] |
Burger J A, Kipps T J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood,2006,107:1761 -1767.
|
| [18] |
Ben Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol,2006,16:38 -52.
|
| [19] |
Giovanni B , Domenico R , Gaia S , et al. Analysis of the role of chemokines in angiogenesis. Immunol Methods,2003,273:3106 -3112.
|
| [20] |
Romagnani P ,Annunziato F ,Lasagni L , et al . Cell cycle 2 dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. Clin Invest,2001,107 :53 -63.
|
| [21] |
Belperio J A, Keane M P, Arenberg D A, et al. CXC chemokines in angiogenesis. Leukoc Biol,2000,68:1 -8.
|
| [22] |
Addison C L , Daniel T O , Burdick M D , et al. The CXC chemokine receptor 2 , CXCR2 , is the putative receptor for ELR+CXC chemokine-induced angiogenic activity. Immunol,2000,165 :5269 -5277.
|
| [23] |
Hao L, Zhang C, Qiu Y, et al . Recombination of CXCR4, VEGF , and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett ,2007,253:34 -42.
|
| [24] |
Liang Z, Brooks J, Willard M, et al . CXCR4/ CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun,2007,359:716 -722.
|
| [25] |
Salvucci O, Bouchard A, Baccarelli A, et al . The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat,2006,97:275 -283.
|
| [26] |
Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res,2002,62:1093 -1102.
|
| [27] |
Manes S, Mira E, Colomer R, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med,2003,198:1381 -1389.
|
| [28] |
Sharma S, Stolina M, Luo J, et al . Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol,2000 ,164:4558 -4563.
|
| [29] |
Yang S C, Hillinger S, Riedl K, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res,2004,10:2891 -2901.
|
| [30] |
Strieter R M, Burdick M D, Mestas J, et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer,2006,42:768 -778.
|
| [31] |
Kato M, Kitayama J, Kazama S, et al . Expression pattern of CXC Chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal cancer. Breast Cancer Res,2003,5 :R144 -R150.
|
| [32] |
Tamamura H, Hori A, Kanzaki N, et al . T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett,2003,550 :79 -83.
|
| [33] |
Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible smal1 interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res,2003,63:4801 -4804.
|
| [34] |
谢竞, 周艳, 范林军, 等. 乳腺癌组织趋化因子受体CCR7 表达及其与淋巴管浸润关系的研究.中华肿瘤防治杂志,2008,15:437 -439.
|
| [35] |
Weninger W, Carlsen H S, G oodarzi M, et al . Naive T cell recruitment to non-lymphoid tissues: a role for endothelium expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis . J Immunol, 2003, 170: 4638 -4648.
|
| [36] |
Cabioglu N, Yazici M S, Arun B, et al . CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in breast cancer. Clin Cancer Res,2005,11:5686 -5693.
|
| [37] |
朱旬, 甄林林, 郑伟, 等. 趋化因子受体CCR7 在乳腺癌淋巴结转移中的作用. 第四军医大学学报,2006,27:1205-1207.
|
| [38] |
Andre F, Cabioglu N, Assi H, et al . Expression of chemokine receptors predicts the site of metastatic relapse in patient s with axillary node positive primary breast cancer. Ann Oncol,2006,17:945 -951.
|
| [39] |
Kirk C J, Hartigan O'Connor D, Nickoloff B J, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res,2001,61:2062 -2070.
|
| [40] |
Dilloo D,Bacon K, Holden W,et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity.Nat Med,1996,2:1098.
|
| [41] |
Zibert A, Balzer S, Dilloo D, et al. CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum Gene Ther, 2004, 15: 21 -34.
|
| [42] |
Gasperini S, Marchi M, Calzetti F, et al. Gene expression and production of the monokine induced by IFN-gamma(MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol,1999,162:4928 -4937.
|
| [43] |
Vicari A P,Ait Yahia S,Chemin K,et al. Antitumor effects of the mouse chemokine 6 Ckine/SLC through angiostatic and immunological mechanisms. J Immunol,2000,165:1992 -2000.
|
| [44] |
Fushimi T, Kojima A, Moore M A, et al. Macrophage inflammatory protein 3 alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest,2000,105:1383 -1389.
|
| [45] |
Fioretti F, Fradelizi D, Stoppacciaro A, et al. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol,1998,161:342 -346.
|
| [46] |
Mule J J, Custer M, Averbook B, et al. RANTES secretion bygene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther,1996,7:1545 -1553.
|
| [47] |
Hmoey B, Muller A, Zlotnik A. Chemokines : agents for the immunol therapy of cancer. Natl Rev Immunol, 2002, 2:175 -184.
|
| [48] |
Hogaboam C M, Bone-Larson C, Matsukawa A, et al. Therapeutic use of chemokines. Curr Pharm Des,2000,6:651 -663.
|